Hartmut Goldschmidt

Active 1993–2026

288
Papers
53,071
Citations
109
h-index
269
i10-index

Citations

Citations per year for Hartmut Goldschmidt1948: 1 citations1984: 1 citations1988: 3 citations1990: 4 citations1993: 3 citations1994: 8 citations1995: 14 citations1996: 9 citations1997: 14 citations1998: 14 citations1999: 6 citations2000: 21 citations2001: 8 citations2002: 10 citations2003: 22 citations2004: 30 citations2005: 41 citations2006: 93 citations2007: 123 citations2008: 141 citations2009: 195 citations2010: 174 citations2011: 182 citations2012: 177 citations2013: 236 citations2014: 244 citations2015: 282 citations2016: 321 citations2017: 419 citations2018: 364 citations2019: 1,655 citations2020: 2,004 citations2021: 2,031 citations2022: 1,747 citations2023: 1,268 citations2024: 2,447 citations2025: 1,075 citations2026: 36 citations1949–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1989: no citations, so this year is not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,689 citing papers, 25.2% of this breakdownGermany: 1,050 citing papers, 7.2% of this breakdownChina: 1,012 citing papers, 6.9% of this breakdownItaly: 914 citing papers, 6.2% of this breakdownUnited Kingdom: 867 citing papers, 5.9% of this breakdownFrance: 778 citing papers, 5.3% of this breakdownSpain: 697 citing papers, 4.7% of this breakdownNetherlands: 504 citing papers, 3.4% of this breakdownCanada: 461 citing papers, 3.1% of this breakdownGreece: 406 citing papers, 2.8% of this breakdownAustralia: 362 citing papers, 2.5% of this breakdownBelgium: 320 citing papers, 2.2% of this breakdown
0%25.2%Other 24.6%

Fields

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Immunology and Microbiology3%
  • Computer Science0.5%
  • Engineering0.4%
  • Health Professions0.4%
  • Other1.4%

Topics

  • Multiple Myeloma Research and Treatments18.9%
  • Protein Degradation and Inhibitors7.8%
  • CAR-T cell therapy research5.7%
  • Peptidase Inhibition and Analysis4.4%
  • Ubiquitin and proteasome pathways2.8%
  • Cancer Treatment and Pharmacology2.7%
  • Other57.7%

Coauthors

All papers

Open in search
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,424

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 cited by 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  4. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 cited by 2,178

  5. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  6. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 247

  7. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 cited by 407

  8. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  9. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 987

  10. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 363

  11. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Leukemia 2018 cited by 453

  12. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,434

  13. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 cited by 327

  14. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 141

  15. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  16. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Jesús F. San Miguel, Sagar Lonial, Graham Jackson, Kenneth C. Anderson, Hervé Avet‐Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth J. Morgan - Blood 2018 cited by 495

  17. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 275

  18. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Hoffmann, Marc S. Raab, Hans Salwender, Katja Weisel, Katja C Weisel, Anne M Asemissen, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Uta Bertsch, Britta Besemer, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Jan Dürig, Roland Fenk, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Thomas Geer, Deniz Gezer, Hartmut Goldschmidt, Hartmut Goldschmidt, Martin Görner, Ullrich Graeven, Jochen Grassinger, Mathias Hänel, Bernhard Heilmeier, Michael Heinsch, Gerhard Held, Martin Hoffmann, Tobias A W Holderried, Olaf Hopfer, Stefanie Huhn, Peter Immenschuh, Dominic Kaddu-Mulindwa, Cyrus Khandanpour, Maika Klaiber-Hakimi, Martine Klausmann, Stefan Klein, Wolfgang Knauf, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Katharina Kriegsmann, Martin Kropff, Paul La Rosée, Steffen P Luntz, Rolf Mahlberg, Elias K Mai, Christoph Mann, Uwe Martens, Ivana von Metzler, Martin Müller, Markus Munder, Michael Neise, Eva Nievergall, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Marc S Raab, Mohammed R Rafiyan, Peter Reimer, Armin Riecke and 27 more - The Lancet Haematology 2022 cited by 154

  19. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 929

  20. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 133

  21. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc S. Raab, Fritz Van Rhee, Saad Z. Usmani, Kenneth H. Shain, Niels Weinhold, Gareth J. Morgan, Ola Landgren - Journal of Clinical Oncology 2024 cited by 119

  22. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose and 65 more - The Lancet Oncology 2019 cited by 385

  23. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 243

  24. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268